Company Encyclopedia
View More
name
SHANGHAI KAIBAO
300039.SZ
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, including Thiopronine for injection and Thiopronine enteric-coated tablets. In addition, the company provides Astragalus and Ginseng Capsules for the treatment of cardiovascular and cerebrovascular diseases.
3.157 T
300039.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking128/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.23%B
    • Profit Margin29.51%A
    • Gross Margin79.63%A
  • Growth ScoreD
    • Revenue YoY-24.97%E
    • Net Profit YoY-0.94%C
    • Total Assets YoY14.57%A
    • Net Assets YoY17.92%A
  • Cash ScoreD
    • Cash Flow Margin338.91%C
    • OCF YoY-24.97%E
  • Operating ScoreD
    • Turnover0.25D
  • Debt ScoreA
    • Gearing Ratio8.32%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SHANGHAI KAIBAO: Net profit for the third quarter was 65.0877 million yuan, a decrease of 13.13%

    SHANGHAI KAIBAO announced that its revenue for the third quarter was 214 million yuan, a decrease of 26.61%; net profit was 65.0877 million yuan, a decrease of 13.13%. Revenue for the first three quarters was 819 million yuan, a decrease of 26.95%; net profit was 187 million yuan, a decrease of 13.83%

    Zhitong·
    SZ
    300039
    -1.23%
    Zhitong·
    SZ
    300039
    -1.23%

    SHANGHAI KAIBAO released its performance for the first half of the year, with a net profit attributable to the parent company of 122 million yuan, a decrease of 14.20%

    According to the Zhitong Finance APP, SHANGHAI KAIBAO released its semi-annual report for 2025, showing an operating income of 605 million yuan, a year-on-year decrease of 27.08%. The net profit attributable to shareholders of the listed company was 122 million yuan, a year-on-year decrease of 14.20%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 117 million yuan, a year-on-year decrease of 17.81%. The basic earnings per share were 0.1166 yuan

    Zhitong·
    SZ
    300039
    -1.23%
    Zhitong·
    SZ
    300039
    -1.23%

    SHANGHAI KAIBAO plans to sell no more than 6.2011 million shares of SHANGHAI YIZHONG at an opportune time

    According to the announcement from SHANGHAI KAIBAO, the company plans to sell its shares in SHANGHAI YIZHONG through centralized bidding, block trading, or inquiry transfer based on market conditions, with the number not exceeding 6.2011 million shares

    Zhitong·
    SZ
    300039
    -1.23%
    SH
    688091
    -1.87%
    Zhitong·
    SZ
    300039
    -1.23%
    SH
    688091
    -1.87%

    The concerted action party of the actual controller of SHANGHAI KAIBAO, Kaiyi Trading, plans to reduce its holdings by no more than 1%

    SHANGHAI KAIBAO announced that its controlling shareholder's concerted actor, Kaiyi Trading, plans to reduce its holdings by no more than 10.46 million shares between July 23, 2025, and October 22, 2025, with a reduction ratio not exceeding 1%

    Zhitong·
    SZ
    300039
    -1.23%
    Zhitong·
    SZ
    300039
    -1.23%

    SHANGHAI KAIBAO has obtained the drug registration certificate for Phlegm-Heat Clearing Capsules

    SHANGHAI KAIBAO recently obtained the "Drug Registration Certificate" for Phlegm-Heat Clearing Capsules issued by the National Medical Products Administration. This drug is an exclusive product of the company, mainly used for clearing heat, resolving phlegm, and detoxifying. Indications include symptoms such as mild fever, cough, and sore throat caused by wind-heat lung disease and novel coronavirus infection

    Zhitong·
    SZ
    300039
    -1.23%
    Zhitong·
    SZ
    300039
    -1.23%
    © 2025 Longbridge｜Disclaimer